Cryotherapy for partial gland ablation of prostate cancer: Oncologic and safety outcomes.
Prostate cancer
cryotherapy
focal therapy
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
revised:
27
01
2023
received:
30
11
2022
accepted:
31
01
2023
medline:
10
5
2023
pubmed:
14
2
2023
entrez:
13
2
2023
Statut:
ppublish
Résumé
Partial gland ablation (PGA) is a new option for treatment of prostate cancer (PCa). Cryotherapy, an early method of PGA, has had favorable evaluations, but few studies have employed a strict protocol using biopsy endpoints in men with clinically significant prostate cancer (csPCa). 143 men with unilateral csPCa were enrolled in a prospective, observational trial of outpatient PGA-cryotherapy. Treatment was a 2-cycle freeze of the affected prostate part. Participants were evaluated with MRI-guided biopsy (MRGB) at baseline and at 6 months and 18 months after treatment. Absence of csPCa upon MRGB was the primary endpoint; quality-of-life at baseline and at 6 months after treatment was assessed by EPIC-CP questionnaires in the domains of urinary and sexual function. Of the 143 participants, 136 (95%) completed MRGB at 6 months after treatment. In 103/136 (76%), the biopsy revealed no csPCa. Of the 103, 71 subsequently had an 18-month comprehensive biopsy; of the 71 with 18-month biopsies, 46 (65%) were found to have no csPCa. MRI lesions became undetectable in 96/130 (74%); declines in median serum PSA levels (6.9 to 2.5 ng/mL), PSA density (0.15 to 0.07), and prostate volume (42 to 34cc) were observed (all p < 0.01). Neither lesion disappearance on MRI nor PSA decline correlated with biopsy outcome. Urinary function was affected only slightly and sexual function moderately. In the near to intermediate term, partial gland ablation with cryotherapy was found to be a safe and moderately effective treatment of intermediate-risk prostate cancer. Eradication of cancer was better determined by MRI-guided biopsy than by MRI or PSA.
Sections du résumé
BACKGROUND
Partial gland ablation (PGA) is a new option for treatment of prostate cancer (PCa). Cryotherapy, an early method of PGA, has had favorable evaluations, but few studies have employed a strict protocol using biopsy endpoints in men with clinically significant prostate cancer (csPCa).
METHODS
143 men with unilateral csPCa were enrolled in a prospective, observational trial of outpatient PGA-cryotherapy. Treatment was a 2-cycle freeze of the affected prostate part. Participants were evaluated with MRI-guided biopsy (MRGB) at baseline and at 6 months and 18 months after treatment. Absence of csPCa upon MRGB was the primary endpoint; quality-of-life at baseline and at 6 months after treatment was assessed by EPIC-CP questionnaires in the domains of urinary and sexual function.
RESULTS
Of the 143 participants, 136 (95%) completed MRGB at 6 months after treatment. In 103/136 (76%), the biopsy revealed no csPCa. Of the 103, 71 subsequently had an 18-month comprehensive biopsy; of the 71 with 18-month biopsies, 46 (65%) were found to have no csPCa. MRI lesions became undetectable in 96/130 (74%); declines in median serum PSA levels (6.9 to 2.5 ng/mL), PSA density (0.15 to 0.07), and prostate volume (42 to 34cc) were observed (all p < 0.01). Neither lesion disappearance on MRI nor PSA decline correlated with biopsy outcome. Urinary function was affected only slightly and sexual function moderately.
CONCLUSION
In the near to intermediate term, partial gland ablation with cryotherapy was found to be a safe and moderately effective treatment of intermediate-risk prostate cancer. Eradication of cancer was better determined by MRI-guided biopsy than by MRI or PSA.
Identifiants
pubmed: 36775929
doi: 10.1002/cam4.5692
pmc: PMC10166973
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9351-9362Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001881
Pays : United States
Organisme : NCI NIH HHS
ID : R01CA195505
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000124
Pays : United States
Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
JAMA Netw Open. 2019 Sep 4;2(9):e1911019
pubmed: 31509206
Eur Urol Focus. 2022 May;8(3):701-709
pubmed: 33926838
Urol Oncol. 2017 Jan;35(1):30.e9-30.e15
pubmed: 27663393
Urology. 2018 Feb;112:126-131
pubmed: 29126844
Lancet. 2017 Feb 25;389(10071):815-822
pubmed: 28110982
J Urol. 2021 Nov;206(5):1177-1183
pubmed: 34251879
Urology. 2002 Jul;60(1):109-14
pubmed: 12100934
J Urol. 2022 Jul;208(1):10-18
pubmed: 35536144
Rev Urol. 2004;6 Suppl 4:S9-S19
pubmed: 16985871
Eur Urol. 2014 Apr;65(4):809-15
pubmed: 23523537
World J Urol. 2018 Feb;36(2):209-213
pubmed: 29149380
J Urol. 2018 Jan;199(1):133-139
pubmed: 28652121
Trials. 2021 Aug 18;22(1):547
pubmed: 34407860
World J Urol. 2021 Apr;39(4):1115-1119
pubmed: 32638084
Urology. 2022 Dec;170:161-167
pubmed: 35907484
PLoS Med. 2007 Oct 16;4(10):e296
pubmed: 17941714
Cancer Med. 2023 Apr;12(8):9351-9362
pubmed: 36775929
Eur Urol. 2022 Jan;81(1):5-33
pubmed: 34489140
Eur Urol. 2019 Jul;76(1):27-30
pubmed: 30904357
J Urol. 2019 Dec;202(6):1188-1198
pubmed: 31347953
J Urol. 2020 Feb;203(2):320-330
pubmed: 31437121
N Engl J Med. 2002 Oct 17;347(16):1233-41
pubmed: 12393820
Cardiovasc Intervent Radiol. 2008 Jan-Feb;31(1):98-106
pubmed: 17593431
Prostate Cancer Prostatic Dis. 2021 Mar;24(1):114-119
pubmed: 32636487
BJU Int. 2023 Jan;131(1):20-31
pubmed: 36083229
Nat Rev Clin Oncol. 2014 Aug;11(8):482-91
pubmed: 24751803
Nature. 2022 Aug;608(7922):360-367
pubmed: 35948708
J Endourol. 2021 Sep;35(9):1290-1299
pubmed: 33559527
Urology. 2019 Apr;126:158-164
pubmed: 30659903
J Urol. 2014 Mar;191(3):638-45
pubmed: 24076307
J Urol. 2017 Jan;197(1):109-114
pubmed: 27475967
Clin Genitourin Cancer. 2018 Apr;16(2):e477-e482
pubmed: 29174470
Eur Urol. 2019 Jul;76(1):98-105
pubmed: 30638633
Eur Urol. 2020 Aug;78(2):155-160
pubmed: 32444261
JAMA. 2020 Jan 14;323(2):149-163
pubmed: 31935027
J Urol. 2021 Mar;205(3):791-799
pubmed: 33021441
World J Urol. 2019 Aug;37(8):1517-1534
pubmed: 30710157
Eur Urol. 2020 Sep;78(3):371-378
pubmed: 32532513
J Urol. 2011 Sep;186(3):865-72
pubmed: 21788038
J Urol. 2020 Aug;204(2):273-280
pubmed: 31967521
Urol Oncol. 2011 May-Jun;29(3):334-42
pubmed: 21555104
Eur Urol. 2016 Jan;69(1):16-40
pubmed: 26427566
J Urol. 2020 Nov;204(5):941-949
pubmed: 32985924